drugset / Trial / NCT05493267
A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB
Phase 4
Recruiting
30 enrolled
Shanghai Pulmonary Hospital, Shanghai, China
Huashan Hospital · collabNo.85 Hospital, Changning, Shanghai, China · collabShanghai Public Health Clinical Center · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
A Exploratory Study of drug combination (zoledronic acid/interleukin 2) that specifically amplifies Vγ2Vδ2 T cells in combination with anti-tuberculosis chemotherapy for the treatment of MDR-TB.
Timeline
- Start
- 2022-08-03
- Primary completion
- 2025-08-03
- Completion
- 2027-08-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zoledronic acid | Other / unclassified | — | Intravenous |
| Subject | recombinant human interleukin | Protein / enzyme biologic | — | Subcutaneous |